Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones.
|
31837333 |
2020 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones.
|
31837333 |
2020 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Lately, GLP-1RAs have spiked the interest of researchers and clinicians due to their beneficial effects on CVD.
|
31825468 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impact of adherence to this medication and its effect on patients with T2DM who switch from loose-dose combination therapy to a FRC of insulin and GLP-1RA have not yet been reported.
|
31808132 |
2020 |
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, our work demonstrates that the inhibition of the G9a/GLP complex by UNC0642 delivered significant neuroprotective effects in 5XFAD mice, point out G9a/GLP as a new target for AD.
|
31804189 |
2019 |
Alzheimer Disease, Early Onset
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and β-Amyloid plaques in an early-onset Alzheimer's disease mouse model.
|
31804189 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Drugs acting as glucagon-like peptide-1 receptor agonists (GLP-1RAs) developed for the management of T2DM reduce body weight and liraglutide is the first GLP-1RA to be approved for the treatment of obesity in patients with and without T2DM.<b>Areas covered</b>: In this review of relevant published material, the authors summarize the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of liraglutide for the treatment of obesity.<b>Expert opinion</b>: Liraglutide effectively reduces body weight and body fat through mechanisms involving reduced appetite and lowered energy intake, independent of its glucose-lowering effects.
|
31790314 |
2020 |
Obesity
|
0.060 |
Biomarker
|
disease |
BEFREE |
Newer GLP-1RAs, such as semaglutide, or other drugs in development for obesity may have advantages over liraglutide.
|
31790314 |
2020 |
Decrease in appetite
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Drugs acting as glucagon-like peptide-1 receptor agonists (GLP-1RAs) developed for the management of T2DM reduce body weight and liraglutide is the first GLP-1RA to be approved for the treatment of obesity in patients with and without T2DM.<b>Areas covered</b>: In this review of relevant published material, the authors summarize the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of liraglutide for the treatment of obesity.<b>Expert opinion</b>: Liraglutide effectively reduces body weight and body fat through mechanisms involving reduced appetite and lowered energy intake, independent of its glucose-lowering effects.
|
31790314 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
PubMed and CENTRAL, along with grey literature sources, were searched from their inception to May 2019 for randomized controlled trials (RCTs) with a duration ≥ 12 weeks, evaluating the safety and efficacy of addition of a GLP-1RA on a SGLT-2i compared to SGLT-2i alone in patients with T2DM.
|
31733280 |
2019 |
Brain Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptor agonists (GLP-1RAs) showed beneficial actions on brain ischemia in animal models, such as the reduction of cerebral infarct area and the improvement of neurological deficit, acting mainly through inhibition of oxidative stress, inflammation, and apoptosis.
|
31680842 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite the early positioning of GLP-1RA in T2D treatment algorithms, GLP-1RA have been prescribed in patients with progressively more advanced disease stage and especially in the presence of cardiovascular disease.
|
31673896 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several GLP-1 receptor agonists (GLP-1RA) have become available for the treatment of type 2 diabetes (T2D), and evidence on their beneficial effects has evolved.
|
31673896 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
PubMed, Embase, and the Cochrane Library were searched for randomized controlled trials (RCTs) comparing SGLT2is plus Dipeptidyl-Peptidase 4 inhibitors (SGLT2is/DPP4is) or glucagon like peptide-1 receptor agonists (SGLT2is/GLP-1RAs) against SGLT2is as monotherapy or add-on to metformin in T2DMs.
|
31642583 |
2020 |
Gastrointestinal Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Combination with GLP-1RAs exhibited more HbA1c reduction (WMD: -0.8; 95% CI, -1.14 to -0.45%), weight loss (-1.46; 95% CI, -2.38 to -0.54 kg), and systolic blood pressure (SBP) reduction (-2.88; 95% CI, -4.52 to -1.25 mmHg) versus SGLT2is alone but increased the gastrointestinal disorder risk (RR: 1.68; 95% CI, 1.14-2.47).
|
31642583 |
2020 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modulation of platelet function by diabetes agents in addition to their hypoglycemic effects would contribute to cardiovascular protection Newly introduced antidiabetic drugs of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors may have anti-platelet effects, and in the case of SGLT2i and GLP-1RA may contribute to their proven cardiovascular benefit that has been shown clinically.
|
31612835 |
2020 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Modulation of platelet function by diabetes agents in addition to their hypoglycemic effects would contribute to cardiovascular protection Newly introduced antidiabetic drugs of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors may have anti-platelet effects, and in the case of SGLT2i and GLP-1RA may contribute to their proven cardiovascular benefit that has been shown clinically.
|
31612835 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ADA-EASD consensus report recommends using glucagon-like peptide-1 receptor agonists (GLP-1RAs) as the first injectable therapy prior to basal insulin in most patients with type 2 diabetes (T2D) not at glycemic goals after oral anti-hyperglycemia medications (OH).
|
31605302 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
As head-to-head trials assessing orally administered semaglutide as an add-on to 1-2 oral antidiabetic drugs (OADs) vs other GLP-1 RAs are limited, a network meta-analysis (NMA) was performed to assess the relative efficacy and safety of orally administered semaglutide 14 mg once-daily (QD) vs injectable GLP-1 RAs in patients with type 2 diabetes inadequately controlled on 1-2 OADs.
|
31599391 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RAs are associated with a reduction in cardiovascular morbidity and mortality in high-risk patients with diabetes.
|
31595657 |
2020 |
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1RAs are associated with a reduction in cardiovascular morbidity and mortality in high-risk patients with diabetes.
|
31595657 |
2020 |
Obesity
|
0.060 |
Biomarker
|
disease |
BEFREE |
The meta-analyses of patient subgroups showed a significant reduction in MACE with GLP-1RAs, irrespective of gender, advanced age and obesity.
|
31595657 |
2020 |
Cardiovascular morbidity
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
GLP-1RAs are associated with a reduction in cardiovascular morbidity and mortality in high-risk patients with diabetes.
|
31595657 |
2020 |
Diabetic Retinopathy
|
0.040 |
Biomarker
|
disease |
BEFREE |
We performed two studies in humans.In study 1, we investigated the effect of GLP-1RA exposure from T2D diagnosis on the severity of DR, as diagnosed with retinal imaging (fundus photography).
|
31589290 |
2020 |
Hypertensive disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
In multivariate analysis, sex, disease duration, HbA1c, micro and macroangiopathy, insulin therapy and hypertension remained strongly associated with severe DR, while no association was found with GLP-1RA exposure (OR1.139 [0.800-1.622], p=0.47).
|
31589290 |
2020 |